#Japan #Tokyo #Cognizant #Kyowa Kirin #Benchling

Cognizant and Benchling: A Revolutionary Partnership for R&D

In a groundbreaking move, Cognizant, a prominent player in the AI and technology services market, has joined forces with Benchling to revolutionize research and development at Kyowa Kirin, a well-known global specialty pharmaceutical company. This partnership aims to implement a state-of-the-art AI platform designed to streamline research processes, enhance data management, and ultimately expedite the drug discovery journey.

A New Era for Research

Announced on August 16, 2026, this collaboration comes at a crucial time for Kyowa Kirin, which operates dedicated research facilities in Tokyo and Fuji, Japan. With the increasing complexity of research needs and an expanding pipeline of potential innovations, Cognizant’s support in deploying Benchling is poised to address these challenges head-on.

The Benchling platform serves as a unified environment where scientists can manage structured data, execute AI-driven models, and automate workflows tailored to scientific experiments. This integration not only enhances efficiency but also fosters better collaboration among research teams.

Key Features of the Partnership

One of the standout features of the Benchling platform is its ability to automatically capture data from laboratory instruments, transforming raw data into accessible, searchable records without the need for manual input. This functionality accelerates the research cycle, enabling Kyowa Kirin’s scientists to focus on what truly matters—innovation.

Moreover, Benchling facilitates molecular design, allowing researchers to utilize historical data and gain insights into complex scientific relationships, significantly improving decision-making processes in drug development.

In instance, the integration streamlines workflows from initial experimental design through to selecting potential drug candidates, compressing timelines and pushing forward the boundaries of scientific exploration.

A Commitment to Excellence

Kyowa Kirin is committed to tackling some of healthcare's toughest challenges by developing therapies that hold transformative potential for patients. The company specializes in treating various critical conditions, including intractable hematologic diseases and rare disorders. According to Takashi Shimada, Head of the Research Division at Kyowa Kirin, the aim of this partnership is to standardize workflows and enhance data structuring in research, establishing a robust foundation for future drug discovery.

Cognizant's contribution to this venture goes beyond mere technical support; it offers a comprehensive suite of services, including platform setup, data migration, and ongoing maintenance—ensuring that researchers can focus more on scientific inquiry and less on administrative hurdles.

Moving Towards a New Future

Sajith Wickramasekara, co-founder and CEO of Benchling, emphasizes the integration of AI into everyday research workflows, stating that it fundamentally impacts both the speed and quality of research outcomes. As the pharmaceutical landscape continues to evolve, the ability to leverage technology in meaningful ways becomes not just beneficial, but essential.

Archana Ramanakumar, Industry Solutions Leader at Cognizant, highlights that the partnership is geared towards redefining scientific excellence and establishing a new benchmark for research and development operations. This commitment to innovation places Kyowa Kirin in a strong position within the competitive biopharma market.

Conclusion

Ultimately, this collaboration between Cognizant and Benchling signifies a step forward in operational efficiency and scientific advancement at Kyowa Kirin. As they harness the power of AI and integrated data management, the future of drug discovery in Japan looks promising, with the potential for groundbreaking developments that can change patient lives across the globe. As the partnership unfolds, the biopharmaceutical industry will undoubtedly watch closely, eager to learn from this innovative approach to research and development.